Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received a suspension order from the Assistant Director, Drugs Control Administration, Delhi, for one store located at Gopal Nagar, New Delhi. The drug license was suspended for one day under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945. The order was received on May 10, 2026. The company has disclosed a potential revenue loss of Rs 0.30 lac (approximately Rs 30,000) due to this suspension. This is a routine regulatory compliance disclosure made under SEBI LODR regulations.
The impact is minimal — only one store is affected for one day with a potential revenue loss of just Rs 0.30 lac, which is negligible for a company of Medplus's scale. No material impact on financial operations or shareholder value is expected.